BioPharmSignal logoBioPharmSignal

Biotech News

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

Praxis Precision Medicines (PRAX)Praxis Precision MedicinesEarnings

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and

Open original release

Related news

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

HRMYHarmony Biosciences2026-04-23 12:05 EST

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

XERSXeris Pharmaceuticals2026-04-23 11:30 EST

Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026

ALKSAlkermes plc2026-04-21 20:05 EST

Alkermes to Report First Quarter Financial Results on May 5, 2026

AXSMAxsome2026-04-08 11:00 EST

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

View all latest news

Praxis Precision Medicines

Praxis Precision Medicines is a neuroscience company focused on precision approaches to brain disease and movement disorders. Its platform aims to translate genetics and neurobiology into treatment options.

Recent company news

PRAXPraxis Precision Medicines2026-06-01 20:15 EST

Praxis Precision Medicines Provides Vormatrigine Program Update

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

PRAXPraxis Precision Medicines2026-05-05 20:01 EST

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

PRAXPraxis Precision Medicines2026-04-14 11:30 EST

Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor

Stock data

Close
315.80 USD
Market cap
7.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States